FDA Granted Fast Track Designation for SIM0505 (CDH6 ADC) for the Treatment of Ovarian Cancer

Rademikibart Phase III Data Presented as Late-Breaking Oral at AAD Annual Meeting

Phase I/II NMBIC Data of SIM0237 Releases as Oral presentation at the 2026 EAU26

Deuremidevir Hydrobromide Dry Suspension Doses First Patient in Phase 3 Clinical Trial for RSV Infection

Novel Anti-Stroke Candidate SIM0811 Doses First Participant in Phase I Clinical Trial

Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease

Simcere Zaiming's a Bispecific ADC SIM0610 Doses First Patient in a Phase I Clinical Trial

Simcere Announces Positive Phase III Topline Data of Zemprocitinib (LNK01001) in Rheumatoid Arthritis

Envafolimab Submits New Drug Application for Advanced Biliary Tract Cancer, Accepted for Review by NMPA

Phase III clinical trial (SCORES) data of Suvemcitug published in Nature Cancer